MTNB Quote, Financials, Valuation and Earnings

Equillium has a net margin of -- compared to Matinas BioPharma Holdings's net margin of -0.06%. Matinas BioPharma Holdings's return on equity of -- beat Equillium's return on equity of -20.35%.

Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 5691.51%. On the other hand Equillium has an analysts' consensus of -- which suggests that it could grow by 380.31%. Given that Matinas BioPharma Holdings has higher upside potential than Equillium, analysts believe Matinas BioPharma Holdings is more attractive than Equillium.

Matinas BioPharma Holdings has a beta of 1.672, which suggesting that the stock is 67.222% more volatile than S&P 500. In comparison Equillium has a beta of 1.782, suggesting its more volatile than the S&P 500 by 78.182%.

Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Equillium offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Equillium pays out -- of its earnings as a dividend.

Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Equillium quarterly revenues of $12.2M. Matinas BioPharma Holdings's net income of -$4.3M is lower than Equillium's net income of -$7K. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Equillium's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.57x versus 0.54x for Equillium. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals has a net margin of -- compared to Matinas BioPharma Holdings's net margin of -172.04%. Matinas BioPharma Holdings's return on equity of -- beat Madrigal Pharmaceuticals's return on equity of -89.04%.

Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 5691.51%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 19.13%. Given that Matinas BioPharma Holdings has higher upside potential than Madrigal Pharmaceuticals, analysts believe Matinas BioPharma Holdings is more attractive than Madrigal Pharmaceuticals.

Matinas BioPharma Holdings has a beta of 1.672, which suggesting that the stock is 67.222% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.418, suggesting its less volatile than the S&P 500 by 141.819%.

Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $62.2M. Matinas BioPharma Holdings's net income of -$4.3M is higher than Madrigal Pharmaceuticals's net income of -$107M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.57x versus -- for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Matinas BioPharma Holdings's net margin of 18.95%. Matinas BioPharma Holdings's return on equity of -- beat Merck &'s return on equity of 29.26%.

Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 5691.51%. On the other hand Merck & has an analysts' consensus of $128.73 which suggests that it could grow by 29.11%. Given that Matinas BioPharma Holdings has higher upside potential than Merck &, analysts believe Matinas BioPharma Holdings is more attractive than Merck &.

Matinas BioPharma Holdings has a beta of 1.672, which suggesting that the stock is 67.222% more volatile than S&P 500. In comparison Merck & has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.746%.

Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.13% to investors and pays a quarterly dividend of $0.81 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend.

Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Merck & quarterly revenues of $16.7B. Matinas BioPharma Holdings's net income of -$4.3M is lower than Merck &'s net income of $3.2B. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Merck &'s PE ratio is 20.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.57x versus 4.01x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Tenon Medical has a net margin of -- compared to Matinas BioPharma Holdings's net margin of -358.96%. Matinas BioPharma Holdings's return on equity of -- beat Tenon Medical's return on equity of -430.31%.

Matinas BioPharma Holdings has a consensus price target of --, signalling upside risk potential of 5691.51%. On the other hand Tenon Medical has an analysts' consensus of -- which suggests that it could grow by 341.99%. Given that Matinas BioPharma Holdings has higher upside potential than Tenon Medical, analysts believe Matinas BioPharma Holdings is more attractive than Tenon Medical.

Matinas BioPharma Holdings has a beta of 1.672, which suggesting that the stock is 67.222% more volatile than S&P 500. In comparison Tenon Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Matinas BioPharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tenon Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Matinas BioPharma Holdings pays -- of its earnings as a dividend. Tenon Medical pays out -- of its earnings as a dividend.

Matinas BioPharma Holdings quarterly revenues are --, which are smaller than Tenon Medical quarterly revenues of $887K. Matinas BioPharma Holdings's net income of -$4.3M is lower than Tenon Medical's net income of -$3.2M. Notably, Matinas BioPharma Holdings's price-to-earnings ratio is -- while Tenon Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Matinas BioPharma Holdings is 0.57x versus 0.17x for Tenon Medical. Usually stocks with elevated PS ratios are considered overvalued.